• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TREPROSTINIL Drug Record

  • Summary
  • Interactions
  • Claims
  • TREPROSTINIL chembl:CHEMBL1237119 Approved

    Alternate Names:

    15AU81
    15-AU-81
    TREPROSTINIL
    LRX-15
    TYVASO
    UT-15
    REMODULIN
    TRESPROSTINIL
    ORENITRAM
    [[(1R,2R,3AS,9AS)-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA[B]NAPHTALEN-5-YL]OXY]ACETIC ACID
    TREPROSTINILO
    TYVASO®
    (1R,2R,3AS,9AS)-[[2,3,3A,4,9,9A-HEXAHYDRO-2-HYDROXY- 1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[F]INDEN-5-YL] OXY]ACETIC ACID
    UNIPROST
    TREPROSTINILUM
    REMODULIN®
    chembl:CHEMBL1237119
    rxcui:343048
    drugbank:00374
    chemidplus:81846-19-7
    pubchem.compound:6918140

    Drug Info:

    Drug Class antihypertensive agents
    Year of Approval 2002
    Drug Class antithrombotic agents
    FDA Approval 2002
    Drug Class small molecule
    Drug Indications Antithrombotic Agents
    Drug Indications Antihypertensive Agents
    Drug Categories platelet aggregation inhibitors excl. heparin
    Drug Categories cytochrome p-450 substrates
    Drug Categories potential qtc-prolonging agents
    Drug Categories prostacycline vasodilator
    Drug Categories qtc prolonging agents
    Drug Categories vasodilating agents
    Drug Categories vasodilation
    (3 More Sources)

    Publications:

    Ali et al., 2006, Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts., Am. J. Respir. Cell Mol. Biol.
    Falcetti et al., 2010, Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension., Am. J. Respir. Crit. Care Med.
    Sprague et al., 2008, Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes., Microcirculation
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Olschewski et al., 2004, Prostacyclin and its analogues in the treatment of pulmonary hypertension., Pharmacol. Ther.
    Bacha NC et al., 2019, Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension., Pediatr Pulmonol
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
  • TREPROSTINIL   PTGIR

    Interaction Score: 2.81

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Prostanoid IP receptor agonist
    Direct Interaction yes
    Specific Action of the Ligand Full agonist

    PMIDs:
    20622039 18574748 11752352 15163595


    Sources:
    TTD DrugBank GuideToPharmacology ChemblInteractions

  • TREPROSTINIL   P2RY12

    Interaction Score: 1.99

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    30485728 17139284 17016423


    Sources:
    TEND TdgClinicalTrial DrugBank

  • TREPROSTINIL   PTGDR

    Interaction Score: 0.45

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TREPROSTINIL   PTGER2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TREPROSTINIL   PTGER3

    Interaction Score: 0.35

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Endogenous Drug? False
    Details of Interaction EP<sub>3</sub>-I isoform
    Specific Action of the Ligand Full agonist

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TREPROSTINIL   PTGER4

    Interaction Score: 0.32

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Agonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TREPROSTINIL   PTGER1

    Interaction Score: 0.3

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TREPROSTINIL   PPARD

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    16239641


    Sources:
    DrugBank

  • TREPROSTINIL   PPARG

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TEND TdgClinicalTrial

  • DrugBank: DB00374

    • Version: 5.1.7

    Alternate Names:
    TREPROSTINIL DrugBank Drug Name
    81846-19-7 CAS Number
    Orenitram Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Ali et al., 2006, Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts., Am. J. Respir. Cell Mol. Biol.
    Bacha NC et al., 2019, Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension., Pediatr Pulmonol
    Falcetti et al., 2010, Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension., Am. J. Respir. Crit. Care Med.

  • TEND: TREPROSTINIL

    • Version: 01-August-2011

    Alternate Names:
    TREPROSTINIL Primary Drug Name

    Drug Info:
    Drug Class antithrombotic agents
    Year of Approval 2002
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: TREPROSTINIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antihypertensive Agents
    Drug Indications Antithrombotic Agents
    Drug Class small molecule

    Publications:

  • TTD: Treprostinil

    • Version: 2020.06.01

    Alternate Names:
    D01WUA TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178102445

    • Version: 29-September-2020

    Alternate Names:
    TREPROSTINIL GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1237119

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1237119

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21